EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials

Sumit Sharma, Dilsher S Dhoot, Dilraj S Grewal, Eric Jung, Fabiana Q Silva, Weiming Du, Hadi Moini, David S Boyer

Ophthalmology Retina · 2026

DOI: 10.1016/j.oret.2026.04.027 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Ophthalmology Retina, 2026. Verfasst von Sumit Sharma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Retinal Vein Occlusion, Visual Acuity. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorRetinal Vein OcclusionVisual AcuityHumansIntravitreal InjectionsFemaleMaleTime FactorsAngiogenesis InhibitorsTreatment OutcomeTomography, Optical CoherenceFollow-Up StudiesAgedMiddle AgedDose-Response Relationship, DrugFluorescein AngiographyDouble-Blind Method

Stichwörter der Autor:innen

AfliberceptClinical trialRetinal vein occlusionVisual acuity.

Substanzen

afliberceptRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
  • California Retina Consultants/Retina Consultants of America, Santa Barbara, California.
  • Duke Eye Center, Durham, North Carolina.
  • Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
  • Retina Vitreous Associates Medical Group, Los Angeles, California. Electronic address: vitdoc@aol.com.

Förderung

  • Regeneron Pharmaceuticals Inc

Zitieren

APA

Sharma, S., Dhoot, D. S., Grewal, D. S., Jung, E., Silva, F. Q., Du, W., Moini, H., & Boyer, D. S. (2026). Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2026.04.027

Vancouver

Sharma S, Dhoot DS, Grewal DS, Jung E, Silva FQ, Du W, et al. Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials. Ophthalmology Retina. 2026. doi:10.1016/j.oret.2026.04.027

BibTeX
@article{Sharma2026,
  author = {Sharma, Sumit and Dhoot, Dilsher S and Grewal, Dilraj S and Jung, Eric and Silva, Fabiana Q and Du, Weiming and Moini, Hadi and Boyer, David S},
  title = {Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials},
  journal = {Ophthalmology Retina},
  year = {2026},
  doi = {10.1016/j.oret.2026.04.027}
}
Kostenlos starten →